Antistax® in Patients With Chronic Venous Insufficiency
Primary Purpose
Venous Insufficiency
Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Antistax®, low dose
Antistax®, high dose
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Venous Insufficiency
Eligibility Criteria
Inclusion Criteria:
- Male or female
- Between 25 and 75 years of age
- CVI I or CVI II (without expanded trophic disturbances)
- Willing and able to give written informed consent prior to participation in the study
Exclusion Criteria:
Concomitant disease(s) exclusion criteria:
- Decompensated cardiac insufficiency
- Edema not due to venous disease of the legs (e.g. latent cardiac insufficiency, renal insufficiency, lymph edema, etc)
- Peripheral arterial disease (ankle/arm pressure index < 0.9)
- Current acute phlebitis or thrombosis
- Renal insufficiency (Serum creatinine > 1.5 mg/dl)
- Liver disease (SGPT (ALAT) > 3x upper limit of normal)
- Other diseases: insulin-dependent diabetes mellitus, neuropathies, hyper- or hypocalcaemia, malignancies
- Anamnestic indications of diabetic microangiopathy or polyneuropathy
- Drug and/or alcohol abuse
- Severe climacteric complaints
- Immobility
- Avalvulia
- Klippel-Trénaunay-Weber-Syndrome (Naevus varicosis osteohypertrophicus, Haemangiectasia hypertrophicans)
- State after pulmonary embolism
- Recognized hypersensitivity to the trial drug ingredients
- Current florid venous ulcus
- Clinical indication for a necessary, specific phlebologic acute treatment, e.g. compressive treatment, phlebectomy, etc.
Previous treatment(s) exclusion criteria:
- Treatment with venous drugs within the last 4 weeks
- Treatment with laxatives which affect fluid or electrolyte balance within the last 8 days
- Changes in or unstable response to treatment with theophylline, diuretics, cardiac glycosides, ACE inhibitors or calcium antagonists within the last 8 days
- Changes in post-menopausal Hormone replacement within the last 2 months
Concomitant treatment/non-drug therapy exclusion criteria:
- Other venous drugs apart from the trial medication
- Compression therapy
- Venous surgery at the leg(s)
- Extensive use (on more than a total of 6 days during the entire trial) of laxatives which affect fluid or electrolyte balance
- Major surgery requiring full anesthesia
Other exclusion criteria:
- Previously studied under this protocol
- Participation in another clinical trial within the previous 90 days or during the present study
- Patients who have visited a sauna or had other thermal applications in the previous day before any visit
- Pregnant or nursing women or inadequate birth control methods (this applies to females of childbearing potential only)
- Patients considered as mentally ill as well as unable to work or with limited working ability, or unable (or only partially able) to follow the spoken or written explanations concerning the trial
- Patients in a bad general health state according to the investigator's judgment
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
Antistax®, low dose
Antistax®, high dose
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Changes from baseline of limb volume
determined by water displacement
Secondary Outcome Measures
Changes of limb volume
determined by water displacement
Measurement of calf circumference
in centimeters
Measurement of ankle circumference
in centimeters
Assessment of subjective symptoms on a visual analogue scale (VAS)
Assessment of global efficacy by patient on a 4-point verbal rating scale
Assessment of global efficacy by investigator on a 4-point verbal rating scale
Assessment of global tolerability by patient on a 4-point verbal rating scale
Assessment of global tolerability by investigator on a 4-point verbal rating scale
Number of patients with adverse events
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02191280
Brief Title
Antistax® in Patients With Chronic Venous Insufficiency
Official Title
The Ability of Antistax® to Improve Chronic Venous Insufficiency (CVI) I and II in Male and Female Patients: a Dose Response Study
Study Type
Interventional
2. Study Status
Record Verification Date
July 2014
Overall Recruitment Status
Completed
Study Start Date
April 1998 (undefined)
Primary Completion Date
September 1998 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
4. Oversight
5. Study Description
Brief Summary
Study to determine the efficacy and tolerability of two dose levels of Antistax relative to placebo in patients suffering from CVI grade I or incipient grade II
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Venous Insufficiency
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
260 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Antistax®, low dose
Arm Type
Experimental
Arm Title
Antistax®, high dose
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Antistax®, low dose
Intervention Type
Drug
Intervention Name(s)
Antistax®, high dose
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Changes from baseline of limb volume
Description
determined by water displacement
Time Frame
Baseline, day 84
Secondary Outcome Measure Information:
Title
Changes of limb volume
Description
determined by water displacement
Time Frame
Baseline, days 42 and 98
Title
Measurement of calf circumference
Description
in centimeters
Time Frame
Baseline, days 42, 84 and 98
Title
Measurement of ankle circumference
Description
in centimeters
Time Frame
Baseline, days 42, 84 and 98
Title
Assessment of subjective symptoms on a visual analogue scale (VAS)
Time Frame
Baseline, days 42, 84 and 98
Title
Assessment of global efficacy by patient on a 4-point verbal rating scale
Time Frame
days 42, 84 and 98
Title
Assessment of global efficacy by investigator on a 4-point verbal rating scale
Time Frame
days 42, 84 and 98
Title
Assessment of global tolerability by patient on a 4-point verbal rating scale
Time Frame
days 42, 84 and 98
Title
Assessment of global tolerability by investigator on a 4-point verbal rating scale
Time Frame
days 42, 84 and 98
Title
Number of patients with adverse events
Time Frame
up to 14 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female
Between 25 and 75 years of age
CVI I or CVI II (without expanded trophic disturbances)
Willing and able to give written informed consent prior to participation in the study
Exclusion Criteria:
Concomitant disease(s) exclusion criteria:
Decompensated cardiac insufficiency
Edema not due to venous disease of the legs (e.g. latent cardiac insufficiency, renal insufficiency, lymph edema, etc)
Peripheral arterial disease (ankle/arm pressure index < 0.9)
Current acute phlebitis or thrombosis
Renal insufficiency (Serum creatinine > 1.5 mg/dl)
Liver disease (SGPT (ALAT) > 3x upper limit of normal)
Other diseases: insulin-dependent diabetes mellitus, neuropathies, hyper- or hypocalcaemia, malignancies
Anamnestic indications of diabetic microangiopathy or polyneuropathy
Drug and/or alcohol abuse
Severe climacteric complaints
Immobility
Avalvulia
Klippel-Trénaunay-Weber-Syndrome (Naevus varicosis osteohypertrophicus, Haemangiectasia hypertrophicans)
State after pulmonary embolism
Recognized hypersensitivity to the trial drug ingredients
Current florid venous ulcus
Clinical indication for a necessary, specific phlebologic acute treatment, e.g. compressive treatment, phlebectomy, etc.
Previous treatment(s) exclusion criteria:
Treatment with venous drugs within the last 4 weeks
Treatment with laxatives which affect fluid or electrolyte balance within the last 8 days
Changes in or unstable response to treatment with theophylline, diuretics, cardiac glycosides, ACE inhibitors or calcium antagonists within the last 8 days
Changes in post-menopausal Hormone replacement within the last 2 months
Concomitant treatment/non-drug therapy exclusion criteria:
Other venous drugs apart from the trial medication
Compression therapy
Venous surgery at the leg(s)
Extensive use (on more than a total of 6 days during the entire trial) of laxatives which affect fluid or electrolyte balance
Major surgery requiring full anesthesia
Other exclusion criteria:
Previously studied under this protocol
Participation in another clinical trial within the previous 90 days or during the present study
Patients who have visited a sauna or had other thermal applications in the previous day before any visit
Pregnant or nursing women or inadequate birth control methods (this applies to females of childbearing potential only)
Patients considered as mentally ill as well as unable to work or with limited working ability, or unable (or only partially able) to follow the spoken or written explanations concerning the trial
Patients in a bad general health state according to the investigator's judgment
12. IPD Sharing Statement
Citations:
PubMed Identifier
33141449
Citation
Martinez-Zapata MJ, Vernooij RW, Simancas-Racines D, Uriona Tuma SM, Stein AT, Moreno Carriles RMM, Vargas E, Bonfill Cosp X. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2020 Nov 3;11(11):CD003229. doi: 10.1002/14651858.CD003229.pub4.
Results Reference
derived
Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1138/1138.2_U99-0196.pdf
Description
Related Info
Learn more about this trial
Antistax® in Patients With Chronic Venous Insufficiency
We'll reach out to this number within 24 hrs